Cargando…

P413 Screening and diagnosis of Candidemia in adult hematological malignancies of northern India

POSTER SESSION 3, SEPTEMBER 23, 2022, 12:30 PM - 1:30 PM: Candidemia is caused by Candida species which has become a common cause of fungal infection in the bloodstream infection throughout the world. In hematological malignancies, patients have a high rate of morbidity and mortality due to Candidem...

Descripción completa

Detalles Bibliográficos
Autores principales: Banerjee, Gopa, Tripathi, Shivangi, Tripathi, Anil Kumar, Verma, Shailendra Prasad
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9509950/
http://dx.doi.org/10.1093/mmy/myac072.P413
_version_ 1784797341840048128
author Banerjee, Gopa
Tripathi, Shivangi
Tripathi, Anil Kumar
Verma, Shailendra Prasad
author_facet Banerjee, Gopa
Tripathi, Shivangi
Tripathi, Anil Kumar
Verma, Shailendra Prasad
author_sort Banerjee, Gopa
collection PubMed
description POSTER SESSION 3, SEPTEMBER 23, 2022, 12:30 PM - 1:30 PM: Candidemia is caused by Candida species which has become a common cause of fungal infection in the bloodstream infection throughout the world. In hematological malignancies, patients have a high rate of morbidity and mortality due to Candidemia. AIM: To identify Candidemia in immunocompromised patients with the help of various conventional methods as well as automated methods for early detection and treatment. MATERIAL AND METHODS: This study was conducted from 2018 to 2021. In this study, we enrolled immunocompromised patients with hematological malignancies. For early diagnosis of Candidemia we did conventional method as well as PCR. Compare the conventional, automated, and PCR methods for diagnosis of Candidemia and was performed antifungal susceptibility testing for treatment in hematological patients. RESULTS: Total 187 patients were enrolled on the basis of febrile neutropenia. A total of 125/187 males (66.8%) and 62/187 females (33.2%) participated in the present study followed by age range from 10 to 77 years (mean = 33.16, standard deviation = 16.29). A total of 5 patients (2.6%) were positive from blood culture, and 9 patients (4.8%) were positive from PCR. In 4 patients of AML C. tropicalis was (3; 1.60%) and C. auris (1; 0.5%) followed by 1 patient with pancytopenia C. tropicalis (1; 0.5%). The sensitivity was done according to the Clinical Laboratory Standards Institute (CLSI) guideline M27-A3 reference document for C. tropicalis (4), and C. auris (1). A total of 4 isolates of C. tropicalis were sensitive to drug VRC (MIC range 0.125 μg/ml), AMP (MIC range 1 μg/ml), FLU (MIC range 1 μg/ml), CAS (MIC range 0.25 μg/ml) and 1 resistant pattern toward FLU (MIC range 4 μg/ml). Candida auris was resistant toward AMP (MIC range 2 μg/ml), FLU (MIC range 64 μg/ml), and sensitive toward CAS (MIC range 0.5 μg/mL). A total of 4 isolates of C. tropicalis was sensitive for drug VRC (80%), AMP (80%), FLU (60%), CAS (80%), and resistant pattern for FLU (20%). Candida auris was resistant toward AMP (20%), FLU (20%), and sensitive toward CAS (20%). In all, 9/187 patients’ blood was positive for fungal infection, primer NL-1 and NL-4 were able to amplify the D1/D2 region of 28S r-DNA of large ribosomal subunit which target rDNA yielding Product of PCR give 600 bp related to all fungus. Primer P4501 and P4502 identify the P-450 lanosterol 14α-demethylase gene which is target Candida species genes single band of around 350 bp. Mannan antigen of Candida was performed by ELISA method for diagnosis of candidemia in hematological patients. CONCLUSION: This present observational study recognizes the main association of Candidemia with hematological malignancies. We try to develop PCR and automated methods in routine mycology laboratory to diagnose Candidemia in an early stage in hematological malignancies along with other immunocompromised patients for better treatment to cure the disease.
format Online
Article
Text
id pubmed-9509950
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-95099502022-09-26 P413 Screening and diagnosis of Candidemia in adult hematological malignancies of northern India Banerjee, Gopa Tripathi, Shivangi Tripathi, Anil Kumar Verma, Shailendra Prasad Med Mycol Oral Presentations POSTER SESSION 3, SEPTEMBER 23, 2022, 12:30 PM - 1:30 PM: Candidemia is caused by Candida species which has become a common cause of fungal infection in the bloodstream infection throughout the world. In hematological malignancies, patients have a high rate of morbidity and mortality due to Candidemia. AIM: To identify Candidemia in immunocompromised patients with the help of various conventional methods as well as automated methods for early detection and treatment. MATERIAL AND METHODS: This study was conducted from 2018 to 2021. In this study, we enrolled immunocompromised patients with hematological malignancies. For early diagnosis of Candidemia we did conventional method as well as PCR. Compare the conventional, automated, and PCR methods for diagnosis of Candidemia and was performed antifungal susceptibility testing for treatment in hematological patients. RESULTS: Total 187 patients were enrolled on the basis of febrile neutropenia. A total of 125/187 males (66.8%) and 62/187 females (33.2%) participated in the present study followed by age range from 10 to 77 years (mean = 33.16, standard deviation = 16.29). A total of 5 patients (2.6%) were positive from blood culture, and 9 patients (4.8%) were positive from PCR. In 4 patients of AML C. tropicalis was (3; 1.60%) and C. auris (1; 0.5%) followed by 1 patient with pancytopenia C. tropicalis (1; 0.5%). The sensitivity was done according to the Clinical Laboratory Standards Institute (CLSI) guideline M27-A3 reference document for C. tropicalis (4), and C. auris (1). A total of 4 isolates of C. tropicalis were sensitive to drug VRC (MIC range 0.125 μg/ml), AMP (MIC range 1 μg/ml), FLU (MIC range 1 μg/ml), CAS (MIC range 0.25 μg/ml) and 1 resistant pattern toward FLU (MIC range 4 μg/ml). Candida auris was resistant toward AMP (MIC range 2 μg/ml), FLU (MIC range 64 μg/ml), and sensitive toward CAS (MIC range 0.5 μg/mL). A total of 4 isolates of C. tropicalis was sensitive for drug VRC (80%), AMP (80%), FLU (60%), CAS (80%), and resistant pattern for FLU (20%). Candida auris was resistant toward AMP (20%), FLU (20%), and sensitive toward CAS (20%). In all, 9/187 patients’ blood was positive for fungal infection, primer NL-1 and NL-4 were able to amplify the D1/D2 region of 28S r-DNA of large ribosomal subunit which target rDNA yielding Product of PCR give 600 bp related to all fungus. Primer P4501 and P4502 identify the P-450 lanosterol 14α-demethylase gene which is target Candida species genes single band of around 350 bp. Mannan antigen of Candida was performed by ELISA method for diagnosis of candidemia in hematological patients. CONCLUSION: This present observational study recognizes the main association of Candidemia with hematological malignancies. We try to develop PCR and automated methods in routine mycology laboratory to diagnose Candidemia in an early stage in hematological malignancies along with other immunocompromised patients for better treatment to cure the disease. Oxford University Press 2022-09-20 /pmc/articles/PMC9509950/ http://dx.doi.org/10.1093/mmy/myac072.P413 Text en © The Author(s) 2022. Published by Oxford University Press on behalf of The International Society for Human and Animal Mycology. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (https://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Oral Presentations
Banerjee, Gopa
Tripathi, Shivangi
Tripathi, Anil Kumar
Verma, Shailendra Prasad
P413 Screening and diagnosis of Candidemia in adult hematological malignancies of northern India
title P413 Screening and diagnosis of Candidemia in adult hematological malignancies of northern India
title_full P413 Screening and diagnosis of Candidemia in adult hematological malignancies of northern India
title_fullStr P413 Screening and diagnosis of Candidemia in adult hematological malignancies of northern India
title_full_unstemmed P413 Screening and diagnosis of Candidemia in adult hematological malignancies of northern India
title_short P413 Screening and diagnosis of Candidemia in adult hematological malignancies of northern India
title_sort p413 screening and diagnosis of candidemia in adult hematological malignancies of northern india
topic Oral Presentations
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9509950/
http://dx.doi.org/10.1093/mmy/myac072.P413
work_keys_str_mv AT banerjeegopa p413screeninganddiagnosisofcandidemiainadulthematologicalmalignanciesofnorthernindia
AT tripathishivangi p413screeninganddiagnosisofcandidemiainadulthematologicalmalignanciesofnorthernindia
AT tripathianilkumar p413screeninganddiagnosisofcandidemiainadulthematologicalmalignanciesofnorthernindia
AT vermashailendraprasad p413screeninganddiagnosisofcandidemiainadulthematologicalmalignanciesofnorthernindia